Yamashita, S.; Hamamoto, S.; Furukawa, J.; Fujita, K.; Takahashi, M.; Miyake, M.; Ito, N.; Iwamoto, H.; Kohjimoto, Y.; Hara, I.
Efficacy and Safety of Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma in Patients 75 Years and Older: Multicenter Retrospective Study. Cancers 2025, 17, 474.
https://doi.org/10.3390/cancers17030474
AMA Style
Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, Ito N, Iwamoto H, Kohjimoto Y, Hara I.
Efficacy and Safety of Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma in Patients 75 Years and Older: Multicenter Retrospective Study. Cancers. 2025; 17(3):474.
https://doi.org/10.3390/cancers17030474
Chicago/Turabian Style
Yamashita, Shimpei, Shuzo Hamamoto, Junya Furukawa, Kazutoshi Fujita, Masayuki Takahashi, Makito Miyake, Noriyuki Ito, Hideto Iwamoto, Yasuo Kohjimoto, and Isao Hara.
2025. "Efficacy and Safety of Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma in Patients 75 Years and Older: Multicenter Retrospective Study" Cancers 17, no. 3: 474.
https://doi.org/10.3390/cancers17030474
APA Style
Yamashita, S., Hamamoto, S., Furukawa, J., Fujita, K., Takahashi, M., Miyake, M., Ito, N., Iwamoto, H., Kohjimoto, Y., & Hara, I.
(2025). Efficacy and Safety of Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma in Patients 75 Years and Older: Multicenter Retrospective Study. Cancers, 17(3), 474.
https://doi.org/10.3390/cancers17030474
